Program
inclisiran
Also written as “Inclisiran”, “Inclisiran Sodium” and “ALN-PCSSC”.
Its studies are mostly in Hypercholesterolemia · Atherosclerosis · Homozygous Familial Hypercholesterolemia · Acute Coronary Syndrome · Hyperlipoproteinemia Type II, led by 2 companies.
Drug pageInclisiran: every studyAll 51 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 3615 open or running | phase 4since Dec 13, 2021 | Nov 3, 2015 | Nov 27, 2026phase 4 · NCT06501443 |
| Alnylam Pharmaceuticals | 10 open or running | phase 1since Dec 5, 2014 | Dec 5, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alnylam Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 5, 2014First study: phase 1 study in HypercholesterolemiaFirst studyNCT02314442 · 70 enrolled · United Kingdom
- Dec 9, 2015Named inclisiranINNProposed as its International Nonproprietary Name in WHO's List 114
TargetBeta
“The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
The one study Alnylam Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02314442Hypercholesterolemia · United Kingdom | 1 | Completed | May 2015 | 70 |
How it is read
Names in the registry
- “Inclisiran”, 16 entries
- “Inclisiran Sodium”, 4 entries
- “inclisiran”, 3 entries
- “ALN-PCSSC”, 3 entries
- “Inclisiran sodium 300 mg”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Atherosclerosis, 7 studies
- Homozygous Familial Hypercholesterolemia, 5 studies
- Acute Coronary Syndrome, 3 studies
- Hyperlipoproteinemia Type II, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.